Skip to main content

Table 5 Antimicrobial susceptibility of S. aureus as classified by CLSI and EUCAST §

From: Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections?

Antimicrobial agenta(n° of strains) CLSI susceptibility breakpoint (mg/L) EUCAST susceptibility breakpoint(mg/L) CLSI %S EUCAST %S Type of discrepancyb
Teicoplanin (56.399) 8 2 99.9 98.4 minor
Gentamicin (45.807) 4 1 93.6 89.1 minor
Amikacin (6.446) 16 8 97.6 92.6 minor
Tobramycin (3.155) 4 1 94.7 88.2 minor
Azithromycin (7.223) 2 1 58.6 56.2 minor
Clarithromycin (7.146) 2 1 58.8 58.5 -
Erytromycin (36.118) 0.5 2 74.8 77.4 minor
Tetracycline (1.864) 4 1 74.6 74.3 -
Doxycycline (5.037) 4 1 97.6 88.7 minor
Minocycline (1.417) 4 0.5 99.4 96.9 minor
Clindamycin (25.879) 0.5 0.25 87.5 87.2 -
Trimethoprim (449) 8 2 91.5 89.1 minor
Rifampin (1.154) 1 0.064 96.4 95.0 minor
  1. § CLSI [11] and EUCAST [13].
  2. a For Penicillin, Oxacillin, Vancomycin, Daptomycin, Ciprofloxacin, Levofloxacin, Ofloxacin, Moxifloxacin, Chloramphenicol, Trimethoprim-sulfamethoxazole, Quinupristin-dalfopristin and Linezolid CLSI and EUCAST suggested the same susceptibility breakpoints.
  3. b Discrepancy as defined in the materials and methods section.